MAGE-A4 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene"
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2014
At a glance
- Drugs CHP-MAGE-A4 (Primary) ; Montanide ISA-51
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 09 Nov 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 09 May 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 10 Oct 2011 New trial record